Study identifier:D8860C00005
ClinicalTrials.gov identifier:NCT03162224
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer
head and neck cancer
Phase 1/2
No
MEDI0457, Durvalumab
All
35
Interventional
18 Years - 99 Years
Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Aug 2022 by MedImmune, LLC
MedImmune, LLC
-
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against Programmed Death Ligand 1 (PD-L1), which blocks the interaction of PD-L1 with PD-1 and Cluster of differentiation 80 (CD80). An initial three to 12 participants (Safety Analysis Run-in participants) will be enrolled and assessed for safety before additional participants are enrolled. The initial safety analysis run-in participants along with an approximate total of 50 participants with human papilloma virus associated recurrent or metastatic head and neck squamous cell cancer (HNSCC) will be enrolled in this study and evaluated also for anti-tumor efficacy to MEDI0457 in combination with durvalumab.
Location
Location
Bronx, NY, United States, 10461
Location
Philadelphia, PA, United States, 19104
Location
Atlanta, GA, United States, 30308
Location
Winston-Salem, NC, United States, 27157
Location
Detroit, MI, United States, 48201
Location
Saint Louis, MO, United States, 63110
Location
Indianapolis, IN, United States, 46202
Location
Morristown, NJ, United States, 07960
Arms | Assigned Interventions |
---|---|
Experimental: First-line Recurrent/Metastatic (1L R/M) Platinum Non-refractory Participants with recurrent or metastatic disease and were non-refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then every 8 weeks (Q8W) and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then every 4 weeks (Q4W) until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first. | Drug: MEDI0457 MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device. Other Name: INO-3112 Device: CELLECTRA®5P device MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device. Other Name: CELLECTRA 2000 Drug: Durvalumab Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks. Other Name: MEDI4736 |
Experimental: 1L R/M Platinum Refractory Participants with R/M disease and were refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first. | Drug: MEDI0457 MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device. Other Name: INO-3112 Device: CELLECTRA®5P device MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device. Other Name: CELLECTRA 2000 Drug: Durvalumab Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks. Other Name: MEDI4736 |
Experimental: Second-line (2L) + R/M Participants with R/M disease and were treated with 1 or more lines of platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first. | Drug: MEDI0457 MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device. Other Name: INO-3112 Device: CELLECTRA®5P device MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device. Other Name: CELLECTRA 2000 Drug: Durvalumab Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks. Other Name: MEDI4736 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.